Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 157346
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 116
  • list Pharmaceuticals and Healthcare

Amyotrophic Lateral Sclerosis (ALS) is a neurological disease that affects nerve cells in the brain and spinal cords which controls the activity of voluntary muscles. It is also termed as Lou Gehrig’s disease. There are several causes behind ALS which includes gene mutation, disorganized immune response, chemical imbalance etc. The symptoms for ALS mainly include fasciculation, respiratory problems, muscles weakness and cramps. The mortality rate in the ALS patients in high due to breathing problem. 

Scope of the Report:

This report studies the Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market by product type and applications/end industries.

Increasing in the number of patients affected with ALS is one of the major factor to drive the growth of ALS treatment market. Sporadic and familial are two types of ALS disease, in which sporadic disease is most common disease found with 90–95% of the overall cases in US and the government initiatives to examination the research for rare disease and FDA approvals creates an opportunity for various market players due to which the global market of amyotrophic lateral sclerosis treatment is expected to expand at healthy CAGR during the forecast period. Due to lower prevalence rate, awareness about the disease and low treatment availability hinder the growth of ALS treatment market.  

The global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

GNT Pharma

Amkor Pharma

Synthetic Biologics

Mitsubishi Tanabe Pharma

Avicena

Sanofi

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Chemotherapy

Stem Cell Therapy

Market Segment by Applications, can be divided into

Hospitals

Diagnostic Centres

Clinics

Retail Pharmacies

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Overview

1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment

1.2 Classification of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment by Types

1.2.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Comparison by Types (2017-2023)

1.2.2 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Market Share by Types in 2017

1.2.3 Chemotherapy

1.2.4 Stem Cell Therapy

1.3 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market by Application

1.3.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Diagnostic Centres

1.3.4 Clinics

1.3.5 Retail Pharmacies

1.4 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market by Regions

1.4.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Status and Prospect (2013-2023)

1.5 Global Market Size of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment (2013-2023)

2 Manufacturers Profiles

2.1 GNT Pharma

2.1.1 Business Overview

2.1.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 GNT Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.2 Amkor Pharma

2.2.1 Business Overview

2.2.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Amkor Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.3 Synthetic Biologics

2.3.1 Business Overview

2.3.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Synthetic Biologics Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.4 Mitsubishi Tanabe Pharma

2.4.1 Business Overview

2.4.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.5 Avicena

2.5.1 Business Overview

2.5.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Avicena Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.6 Sanofi

2.6.1 Business Overview

2.6.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Sanofi Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue, Gross Margin and Market Share (2016-2017)

3 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Competition, by Players

3.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Players Market Share

3.2.2 Top 10 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Players Market Share

3.3 Market Competition Trend

4 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Regions

4.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Market Share by Regions

4.2 North America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

4.3 Europe Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

4.5 South America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

5 North America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries

5.1 North America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries (2013-2018)

5.2 USA Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

5.3 Canada Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

5.4 Mexico Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

6 Europe Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries

6.1 Europe Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries (2013-2018)

6.2 Germany Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

6.3 UK Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

6.4 France Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

6.5 Russia Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

6.6 Italy Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries

7.1 Asia-Pacific Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries (2013-2018)

7.2 China Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

7.3 Japan Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

7.4 Korea Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

7.5 India Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

8 South America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries

8.1 South America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries (2013-2018)

8.2 Brazil Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

8.3 Argentina Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

8.4 Colombia Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment by Countries

9.1 Middle East and Africa Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue by Countries (2013-2018)

9.2 Saudi Arabia Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

9.3 UAE Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

9.4 Egypt Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

9.5 Nigeria Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

9.6 South Africa Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Growth Rate (2013-2018)

10 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Segment by Type

10.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue and Market Share by Type (2013-2018)

10.2 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Forecast by Type (2018-2023)

10.3 Chemotherapy Revenue Growth Rate (2013-2023)

10.4 Stem Cell Therapy Revenue Growth Rate (2013-2023)

11 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Segment by Application

11.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Market Share by Application (2013-2018)

11.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Diagnostic Centres Revenue Growth (2013-2018)

11.5 Clinics Revenue Growth (2013-2018)

11.6 Retail Pharmacies Revenue Growth (2013-2018)

12 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size Forecast (2018-2023)

12.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size Forecast (2018-2023)

12.2 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Forecast by Regions (2018-2023)

12.3 North America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Market Forecast (2018-2023)

12.4 Europe Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Market Forecast (2018-2023)

12.6 South America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Picture

Table Product Specifications of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment

Please fill the form below, to recieve the report sample


+1